Logo image of OMER

OMEROS CORP (OMER) Stock Price, Quote, News and Overview

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD

3.21  0 (0%)

OMER Quote, Performance and Key Statistics

OMEROS CORP

NASDAQ:OMER (6/23/2025, 1:26:56 PM)

3.21

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High13.6
52 Week Low2.97
Market Cap188.07M
Shares58.59M
Float56.02M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-05 2025-08-05
IPO10-08 2009-10-08


OMER short term performance overview.The bars show the price performance of OMER in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

OMER long term performance overview.The bars show the price performance of OMER in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30 -40

The current stock price of OMER is 3.21 USD. In the past month the price increased by 3.22%. In the past year, price decreased by -19.14%.

OMEROS CORP / OMER Daily stock chart

OMER Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 55.93 729.34B
JNJ JOHNSON & JOHNSON 15.01 362.93B
NVO NOVO-NORDISK A/S-SPONS ADR 19.11 308.19B
NVS NOVARTIS AG-SPONSORED ADR 14.1 231.35B
AZN ASTRAZENECA PLC-SPONS ADR 16.03 218.67B
MRK MERCK & CO. INC. 10.21 199.68B
PFE PFIZER INC 7.47 136.27B
SNY SANOFI-ADR 10.71 117.01B
BMY BRISTOL-MYERS SQUIBB CO 6.36 94.94B
GSK GSK PLC-SPON ADR 8.61 77.51B
ZTS ZOETIS INC 26.16 70.11B
HLN HALEON PLC-ADR 21.31 46.97B

About OMER

Company Profile

OMER logo image Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Company Info

OMEROS CORP

201 Elliott Avenue West

Seattle WASHINGTON 98119 US

CEO: Gregory A. Demopulos

Employees: 202

OMER Company Website

OMER Investor Relations

Phone: 12066765000

OMEROS CORP / OMER FAQ

What is the stock price of OMEROS CORP today?

The current stock price of OMER is 3.21 USD.


What is the ticker symbol for OMEROS CORP stock?

The exchange symbol of OMEROS CORP is OMER and it is listed on the Nasdaq exchange.


On which exchange is OMER stock listed?

OMER stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OMEROS CORP stock?

10 analysts have analysed OMER and the average price target is 30.6 USD. This implies a price increase of 853.27% is expected in the next year compared to the current price of 3.21. Check the OMEROS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OMEROS CORP worth?

OMEROS CORP (OMER) has a market capitalization of 188.07M USD. This makes OMER a Micro Cap stock.


How many employees does OMEROS CORP have?

OMEROS CORP (OMER) currently has 202 employees.


What are the support and resistance levels for OMEROS CORP (OMER) stock?

OMEROS CORP (OMER) has a support level at 3.16 and a resistance level at 4.82. Check the full technical report for a detailed analysis of OMER support and resistance levels.


Should I buy OMEROS CORP (OMER) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OMEROS CORP (OMER) stock pay dividends?

OMER does not pay a dividend.


When does OMEROS CORP (OMER) report earnings?

OMEROS CORP (OMER) will report earnings on 2025-08-05.


What is the Price/Earnings (PE) ratio of OMEROS CORP (OMER)?

OMEROS CORP (OMER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.65).


What is the Short Interest ratio of OMEROS CORP (OMER) stock?

The outstanding short interest for OMEROS CORP (OMER) is 21.85% of its float. Check the ownership tab for more information on the OMER short interest.


OMER Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to OMER. When comparing the yearly performance of all stocks, OMER is a bad performer in the overall market: 94.23% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OMER Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to OMER. OMER has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OMER Financial Highlights

Over the last trailing twelve months OMER reported a non-GAAP Earnings per Share(EPS) of -2.65. The EPS decreased by -34.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -65.08%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%7.94%
Sales Q2Q%N/A
EPS 1Y (TTM)-34.52%
Revenue 1Y (TTM)N/A

OMER Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to OMER. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners47.43%
Ins Owners4.37%
Short Float %21.85%
Short Ratio11.79
Analysts
Analysts80
Price Target30.6 (853.27%)
EPS Next Y28.37%
Revenue Next YearN/A